{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:21:48Z","timestamp":1790108508362,"version":"4.0.1"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11864-025-01333-5","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T16:47:15Z","timestamp":1755190035000},"page":"726-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies"],"prefix":"10.1007","volume":"26","author":[{"given":"Hue T. T.","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy M.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duc V.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jena C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang M.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy L.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh T. T.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung S.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giang H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"1333_CR1","doi-asserted-by":"publisher","first-page":"1071983","DOI":"10.3389\/fimmu.2023.1071983","volume":"14","author":"T Watanabe","year":"2023","unstructured":"Watanabe T, Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol. 2023;14:1071983. https:\/\/doi.org\/10.3389\/fimmu.2023.1071983.","journal-title":"Front Immunol"},{"key":"1333_CR2","doi-asserted-by":"publisher","unstructured":"Eshaq AM, Flanagan TW, Ba Abbad AA, Makarem ZAA, Bokir MS, Alasheq AK, et al. Immune checkpoint Inhibitor-Associated cutaneous adverse events: mechanisms of occurrence. Int J Mol Sci. 2024;26(1). https:\/\/doi.org\/10.3390\/ijms26010088.","DOI":"10.3390\/ijms26010088"},{"key":"1333_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint Blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29\u201339. https:\/\/doi.org\/10.1016\/j.intimp.2018.06.001.","journal-title":"Int Immunopharmacol"},{"issue":"Pt 2","key":"1333_CR4","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"M Arafat Hossain","year":"2024","unstructured":"Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143(Pt 2):113365. https:\/\/doi.org\/10.1016\/j.intimp.2024.113365.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"1333_CR5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/1535-7163.Mct-23-0043","volume":"22","author":"G Rodr\u00edguez","year":"2023","unstructured":"Rodr\u00edguez G, de Montes AL, Spencer LM, Chimeric Antigen Receptor T, Cells. Immunotherapy for the treatment of leukemia, lymphoma, and myeloma. Mol Cancer Ther. 2023;22(11):1261\u20139. https:\/\/doi.org\/10.1158\/1535-7163.Mct-23-0043.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1333_CR6","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1078-0432.Ccr-15-1433","volume":"22","author":"MV Maus","year":"2016","unstructured":"Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res. 2016;22(8):1875\u201384. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-1433.","journal-title":"Clin Cancer Res"},{"key":"1333_CR7","doi-asserted-by":"publisher","unstructured":"Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-Cells for Cancer therapy. J Natl Cancer Inst. 2016;108(7). https:\/\/doi.org\/10.1093\/jnci\/djv439.","DOI":"10.1093\/jnci\/djv439"},{"key":"1333_CR8","doi-asserted-by":"publisher","first-page":"108106","DOI":"10.1016\/j.pharmthera.2021.108106","volume":"236","author":"C Ceci","year":"2022","unstructured":"Ceci C, Lacal PM, Graziani G. Antibody-drug conjugates: resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacol Ther. 2022;236:108106. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108106.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"1333_CR9","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/s1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254\u201362. https:\/\/doi.org\/10.1016\/s1470-2045(16)30030-4.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1333_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361. https:\/\/doi.org\/10.1038\/s41573-023-00709-2.","journal-title":"Nat Rev Drug Discov"},{"key":"1333_CR11","doi-asserted-by":"publisher","first-page":"1076473","DOI":"10.3389\/fphar.2023.1076473","volume":"14","author":"W Lu","year":"2023","unstructured":"Lu W, Zhang H, Guo Q, Gou Z, Yao J. Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis. Front Pharmacol. 2023;14:1076473. https:\/\/doi.org\/10.3389\/fphar.2023.1076473.","journal-title":"Front Pharmacol"},{"issue":"36","key":"1333_CR12","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/jco.21.01440.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1333_CR13","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-Cell therapies for cancer: A translational. Sci Rev Jama. 2024;332(22):1924\u201335. https:\/\/doi.org\/10.1001\/jama.2024.19462.","journal-title":"Sci Rev Jama"},{"issue":"1","key":"1333_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"key":"1333_CR15","doi-asserted-by":"publisher","unstructured":"Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5). https:\/\/doi.org\/10.3390\/cancers9050052.","DOI":"10.3390\/cancers9050052"},{"issue":"6","key":"1333_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/carcin\/bgad038","volume":"44","author":"D Chen","year":"2023","unstructured":"Chen D, Hong R, Cao Y, Wu Q, Wang Y, Chen J, et al. Combined Wee1 and EGFR Inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma. Carcinogenesis. 2023;44(6):451\u201362. https:\/\/doi.org\/10.1093\/carcin\/bgad038.","journal-title":"Carcinogenesis"},{"key":"1333_CR17","doi-asserted-by":"publisher","first-page":"804212","DOI":"10.3389\/fonc.2022.804212","volume":"12","author":"Y Li","year":"2022","unstructured":"Li Y, Fu R, Jiang T, Duan D, Wu Y, Li C, et al. Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies. Front Oncol. 2022;12:804212. https:\/\/doi.org\/10.3389\/fonc.2022.804212.","journal-title":"Front Oncol"},{"issue":"1","key":"1333_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/jco.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600-Mutant anaplastic thyroid Cancer. J Clin Oncol. 2018;36(1):7\u201313. https:\/\/doi.org\/10.1200\/jco.2017.73.6785.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1333_CR19","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK Inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1210093.","journal-title":"N Engl J Med"},{"issue":"7","key":"1333_CR20","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus Trametinib versus Dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx176.","journal-title":"Ann Oncol"},{"issue":"10","key":"1333_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/s1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland \u00c5, et al. Dabrafenib plus Trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307\u201316. https:\/\/doi.org\/10.1016\/s1470-2045(17)30679-4.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1333_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5029.","journal-title":"JAMA Oncol."},{"key":"1333_CR23","doi-asserted-by":"publisher","unstructured":"Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, et al.\u00a0Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, Phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5029.\u00a0","DOI":"10.1001\/jamaoncol.2017.5029"},{"issue":"1","key":"1333_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s1470-2045(21)00578-7","volume":"23","author":"PY Wen","year":"2022","unstructured":"Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos F, et al. Dabrafenib plus Trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022;23(1):53\u201364. https:\/\/doi.org\/10.1016\/s1470-2045(21)00578-7.","journal-title":"Lancet Oncol"},{"issue":"10324","key":"1333_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0140-6736(21)02175-9","volume":"399","author":"DM Gershenson","year":"2022","unstructured":"Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial. Lancet. 2022;399(10324):541\u201353. https:\/\/doi.org\/10.1016\/s0140-6736(21)02175-9.","journal-title":"Lancet"},{"issue":"20","key":"1333_CR26","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, hormone Receptor-Positive advanced breast Cancer. N Engl J Med. 2019;380(20):1929\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1813904.","journal-title":"N Engl J Med"},{"issue":"5","key":"1333_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15(5):273\u201391. https:\/\/doi.org\/10.1038\/nrclinonc.2018.28.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1333_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997\u20131007. https:\/\/doi.org\/10.1056\/NEJMoa1315226.","journal-title":"N Engl J Med"},{"issue":"4","key":"1333_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ajh.25711","volume":"95","author":"M Dreyling","year":"2020","unstructured":"Dreyling M, Santoro A, Mollica L, Lepp\u00e4 S, Follows G, Lenz G, et al. Long-term safety and efficacy of the PI3K inhibitor Copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2020;95(4):362\u201371. https:\/\/doi.org\/10.1002\/ajh.25711.","journal-title":"Am J Hematol"},{"issue":"23","key":"1333_CR30","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M, Nagy Z, Ill\u00e9s \u00c1, Etienne G, et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood. 2018;132(23):2446\u201355. https:\/\/doi.org\/10.1182\/blood-2018-05-850461.","journal-title":"Blood"},{"issue":"7711","key":"1333_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","volume":"558","author":"Q Venot","year":"2018","unstructured":"Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540\u20136. https:\/\/doi.org\/10.1038\/s41586-018-0217-9.","journal-title":"Nature"},{"key":"1333_CR32","doi-asserted-by":"publisher","first-page":"108011","DOI":"10.1016\/j.bioorg.2024.108011","volume":"154","author":"M Ashadul Sk","year":"2025","unstructured":"Ashadul Sk M, Matada KH, Pal GSP, B R, Mounika VM. Current developments in PI3K-based anticancer agents: designing strategies, biological activity, selectivity, structure-activity correlation, and Docking insight. Bioorg Chem. 2025;154:108011. https:\/\/doi.org\/10.1016\/j.bioorg.2024.108011.","journal-title":"Bioorg Chem"},{"issue":"6","key":"1333_CR33","doi-asserted-by":"publisher","first-page":"e15492","DOI":"10.1111\/dth.15492","volume":"35","author":"G Gullo","year":"2022","unstructured":"Gullo G, Rubatto M, Fava P, Brizio M, Tonella L, Ribero S, et al. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study. Dermatol Ther. 2022;35(6):e15492. https:\/\/doi.org\/10.1111\/dth.15492.","journal-title":"Dermatol Ther"},{"issue":"12","key":"1333_CR34","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1111\/ijd.17479","volume":"63","author":"CO Akpala","year":"2024","unstructured":"Akpala CO, Erfani YJ, Young J, Saeidi V, Todd A, Chelf C, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis-like eruptions in patients treated with immune checkpoint inhibitors: a systematic review. Int J Dermatol. 2024;63(12):e397\u2013404. https:\/\/doi.org\/10.1111\/ijd.17479.","journal-title":"Int J Dermatol"},{"issue":"23","key":"1333_CR35","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1056\/NEJMra2204547","volume":"391","author":"D Kroshinsky","year":"2024","unstructured":"Kroshinsky D, Cardones ARG, Blumenthal KG. Drug reaction with eosinophilia and systemic symptoms. N Engl J Med. 2024;391(23):2242\u201354. https:\/\/doi.org\/10.1056\/NEJMra2204547.","journal-title":"N Engl J Med"},{"issue":"1","key":"1333_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","volume":"10","author":"SI Hung","year":"2024","unstructured":"Hung SI, Mockenhaupt M, Blumenthal KG, Abe R, Ueta M, Ingen-Housz-Oro S, et al. Severe cutaneous adverse reactions. Nat Rev Dis Primers. 2024;10(1):30. https:\/\/doi.org\/10.1038\/s41572-024-00514-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1333_CR37","doi-asserted-by":"publisher","first-page":"28492","DOI":"10.1038\/s41598-024-69054-7","volume":"14","author":"LCE Chan","year":"2024","unstructured":"Chan LCE, Sultana R, Choo KJL, Yeo YW, Pang SM, Lee HY. Viral reactivation and clinical outcomes in drug reaction with eosinophilia and systemic symptoms (DRESS). Sci Rep. 2024;14(1):28492. https:\/\/doi.org\/10.1038\/s41598-024-69054-7.","journal-title":"Sci Rep"},{"issue":"10","key":"1333_CR38","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","volume":"159","author":"Y Du","year":"2023","unstructured":"Du Y, Wu W, Chen M, Dong Z, Wang F. Cutaneous adverse events and Cancer survival prognosis with immune checkpoint inhibitor treatment: A systematic review and Meta-Analysis. JAMA Dermatol. 2023;159(10):1093\u2013101. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3003.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1333_CR39","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","volume":"88","author":"S Zhang","year":"2023","unstructured":"Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, et al. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study. J Am Acad Dermatol. 2023;88(5):1024\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.048.","journal-title":"J Am Acad Dermatol"},{"key":"1333_CR40","doi-asserted-by":"publisher","unstructured":"Curkovic NB, Bai K, Ye F, Johnson DB. Incidence of cutaneous immune-Related adverse events and outcomes in immune checkpoint Inhibitor-Containing regimens: A systematic review and Meta-Analysis. Cancers (Basel). 2024;16(2). https:\/\/doi.org\/10.3390\/cancers16020340.","DOI":"10.3390\/cancers16020340"},{"issue":"13","key":"1333_CR41","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1158\/1078-0432.Ccr-23-3431","volume":"30","author":"ME Lacouture","year":"2024","unstructured":"Lacouture ME, Goleva E, Shah N, Rotemberg V, Kraehenbuehl L, Ketosugbo KF, et al. Immunologic profiling of Immune-Related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways. Clin Cancer Res. 2024;30(13):2822\u201334. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-3431.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1333_CR42","doi-asserted-by":"publisher","first-page":"217.e1","DOI":"10.1016\/j.jaad.2014.04.013","volume":"71","author":"CM Reyes-Habito","year":"2014","unstructured":"Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy. J Am Acad Dermatol. 2014;71(2):217\u2013.e11 https:\/\/doi.org\/10.1016\/j.jaad.2014.04.013. quiz 27\u2009\u2212\u20098.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1333_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221\u201336. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.033. quiz 37\u2013\u20098.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"1333_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31\u20139. https:\/\/doi.org\/10.1007\/s40257-018-0384-3.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"1333_CR45","doi-asserted-by":"publisher","first-page":"6805","DOI":"10.3390\/curroncol30070498","volume":"30","author":"YS Teng","year":"2023","unstructured":"Teng YS, Yu S. Molecular mechanisms of cutaneous immune-Related adverse events (irAEs) induced by immune checkpoint inhibitors. Curr Oncol. 2023;30(7):6805\u201319. https:\/\/doi.org\/10.3390\/curroncol30070498.","journal-title":"Curr Oncol"},{"key":"1333_CR46","doi-asserted-by":"publisher","first-page":"928621","DOI":"10.3389\/fimmu.2022.928621","volume":"13","author":"P Cao","year":"2022","unstructured":"Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: A systematic review. Front Immunol. 2022;13:928621. https:\/\/doi.org\/10.3389\/fimmu.2022.928621.","journal-title":"Front Immunol"},{"key":"1333_CR47","doi-asserted-by":"publisher","first-page":"1196946","DOI":"10.3389\/fmed.2023.1196946","volume":"10","author":"WH Toh","year":"2023","unstructured":"Toh WH, Lee HE, Chen CB. Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches. Front Med (Lausanne). 2023;10:1196946. https:\/\/doi.org\/10.3389\/fmed.2023.1196946.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"1333_CR48","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","volume":"158","author":"MS Asdourian","year":"2022","unstructured":"Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: A systematic review. JAMA Dermatol. 2022;158(8):933\u201341. https:\/\/doi.org\/10.1001\/jamadermatol.2022.1624.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1333_CR49","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1535-7163.Mct-22-0323","volume":"21","author":"RP Agashe","year":"2022","unstructured":"Agashe RP, Lippman SM, Kurzrock R. JAK: not just another kinase. Mol Cancer Ther. 2022;21(12):1757\u201364. https:\/\/doi.org\/10.1158\/1535-7163.Mct-22-0323.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1333_CR50","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/jdv.18810","volume":"37","author":"AK Gupta","year":"2023","unstructured":"Gupta AK, Wang T, Polla Ravi S, Bamimore MA, Piguet V, Tosti A. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors. J Eur Acad Dermatol Venereol. 2023;37(4):666\u201379. https:\/\/doi.org\/10.1111\/jdv.18810.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"16","key":"1333_CR51","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2118828.","journal-title":"N Engl J Med"},{"issue":"2","key":"1333_CR52","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamadermatol.2018.4093","volume":"155","author":"C Ekelem","year":"2019","unstructured":"Ekelem C, Juhasz M, Khera P, Mesinkovska NA. Utility of Naltrexone treatment for chronic inflammatory dermatologic conditions: A systematic review. JAMA Dermatol. 2019;155(2):229\u201336. https:\/\/doi.org\/10.1001\/jamadermatol.2018.4093.","journal-title":"JAMA Dermatol"},{"issue":"30","key":"1333_CR53","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/jco.18.02141","volume":"37","author":"GS Phillips","year":"2019","unstructured":"Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, et al. Treatment outcomes of Immune-Related cutaneous adverse events. J Clin Oncol. 2019;37(30):2746\u201358. https:\/\/doi.org\/10.1200\/jco.18.02141.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1333_CR54","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s13555-024-01198-w","volume":"14","author":"V Madan","year":"2024","unstructured":"Madan V, Ortiz-L\u00f3pez LI, Sakunchotpanit G, Chen R, Nayudu K, Nambudiri VE. Psoriasis in the era of targeted Cancer therapeutics: A systematic review on de Novo and Pre-existing psoriasis in oncologic patients treated with emerging Anti-neoplastic agents. Dermatol Ther (Heidelb). 2024;14(7):1755\u201366. https:\/\/doi.org\/10.1007\/s13555-024-01198-w.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1333_CR55","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","volume":"87","author":"JT Said","year":"2022","unstructured":"Said JT, Elman SA, Perez-Chada LM, Mita C, Merola JF, LeBoeuf NR. Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review. J Am Acad Dermatol. 2022;87(2):399\u2013400. https:\/\/doi.org\/10.1016\/j.jaad.2022.02.030.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1333_CR56","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","volume":"84","author":"V Nikolaou","year":"2021","unstructured":"Nikolaou V, Sibaud V, Fattore D, Sollena P, Ortiz-Brugu\u00e9s A, Giacchero D, et al. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European network for cutaneous adverse event to oncologic drugs (ENCADO) group. J Am Acad Dermatol. 2021;84(5):1310\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.137.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1333_CR57","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2326-6066.Cir-18-0682","volume":"7","author":"D Johnson","year":"2019","unstructured":"Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, et al. IL17A Blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol Res. 2019;7(6):860\u20135. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0682.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"1333_CR58","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/1759-7714.15249","volume":"15","author":"C Mimura","year":"2024","unstructured":"Mimura C, Nagano T, Miwa N, Matsumura K, Yamada J, Satoh H, et al. Mechanism of action of adapalene for treating EGFR-TKI-induced skin disorder. Thorac Cancer. 2024;15(9):722\u20139. https:\/\/doi.org\/10.1111\/1759-7714.15249.","journal-title":"Thorac Cancer"},{"issue":"10","key":"1333_CR59","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/cup.12202","volume":"40","author":"LA Brodell","year":"2013","unstructured":"Brodell LA, Hepper D, Lind A, Gru AA, Anadkat MJ. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors. J Cutan Pathol. 2013;40(10):865\u201370. https:\/\/doi.org\/10.1111\/cup.12202.","journal-title":"J Cutan Pathol"},{"issue":"3","key":"1333_CR60","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1172\/jci128678","volume":"130","author":"TK Satoh","year":"2020","unstructured":"Satoh TK, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer HD, et al. IL-36\u03b3 drives skin toxicity induced by EGFR\/MEK Inhibition and commensal Cutibacterium acnes. J Clin Invest. 2020;130(3):1417\u201330. https:\/\/doi.org\/10.1172\/jci128678.","journal-title":"J Clin Invest"},{"issue":"2","key":"1333_CR61","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","volume":"32","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fern\u00e1ndez-Pe\u00f1as P, Santini D, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice Guidelines(\u2606). Ann Oncol. 2021;32(2):157\u201370. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.005.","journal-title":"Ann Oncol"},{"issue":"6","key":"1333_CR62","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/ajco.13740","volume":"18","author":"M Gorji","year":"2022","unstructured":"Gorji M, Joseph J, Pavlakis N, Smith SD. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis. Asia Pac J Clin Oncol. 2022;18(6):526\u201339. https:\/\/doi.org\/10.1111\/ajco.13740.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4","key":"1333_CR63","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/10781552211009291","volume":"27","author":"J Chen","year":"2021","unstructured":"Chen J, Wang Z. How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs. J Oncol Pharm Pract. 2021;27(4):919\u201329. https:\/\/doi.org\/10.1177\/10781552211009291.","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"1333_CR64","doi-asserted-by":"publisher","first-page":"8655","DOI":"10.1007\/s00520-022-07175-3","volume":"30","author":"JGP Pandy","year":"2022","unstructured":"Pandy JGP, Franco PIG, Li RK. Prophylactic strategies for hand-foot syndrome\/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer. 2022;30(11):8655\u201366. https:\/\/doi.org\/10.1007\/s00520-022-07175-3.","journal-title":"Support Care Cancer"},{"issue":"2","key":"1333_CR65","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/jdv.13443","volume":"30","author":"L Peuvrel","year":"2016","unstructured":"Peuvrel L, Qu\u00e9reux G, Saint-Jean M, Brocard A, Nguyen JM, Khammari A, et al. Profile of vemurafenib-induced severe skin toxicities. J Eur Acad Dermatol Venereol. 2016;30(2):250\u20137. https:\/\/doi.org\/10.1111\/jdv.13443.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1333_CR66","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s13063-022-06353-2","volume":"23","author":"A Santhosh","year":"2022","unstructured":"Santhosh A, Kumar A, Pramanik R, Gogia A, Prasad CP, Gupta I, et al. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). Trials. 2022;23(1):420. https:\/\/doi.org\/10.1186\/s13063-022-06353-2.","journal-title":"Trials"},{"issue":"8","key":"1333_CR67","doi-asserted-by":"publisher","first-page":"e72245","DOI":"10.1371\/journal.pone.0072245","volume":"8","author":"M Chen","year":"2013","unstructured":"Chen M, Zhang L, Wang Q, Shen J. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review. PLoS ONE. 2013;8(8):e72245. https:\/\/doi.org\/10.1371\/journal.pone.0072245.","journal-title":"PLoS ONE"},{"issue":"7","key":"1333_CR68","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1001\/jamadermatol.2017.0989","volume":"153","author":"A Freites-Martinez","year":"2017","unstructured":"Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol. 2017;153(7):694\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0989.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1333_CR69","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40257-023-00790-8","volume":"24","author":"CJ Fay","year":"2023","unstructured":"Fay CJ, Jakuboski S, McLellan B, Allais BS, Semenov Y, Larocca CA, et al. Diagnosis and management of dermatologic adverse events from systemic melanoma therapies. Am J Clin Dermatol. 2023;24(5):765\u201385. https:\/\/doi.org\/10.1007\/s40257-023-00790-8.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1333_CR70","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00403-024-03694-7","volume":"317","author":"L Mager","year":"2025","unstructured":"Mager L, Plaza JA, Sopkovich J, Kaffenberger BH, Dulmage B. Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review. Arch Dermatol Res. 2025;317(1):234. https:\/\/doi.org\/10.1007\/s00403-024-03694-7.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1333_CR71","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/cji.0000000000000498","volume":"47","author":"E Olsen","year":"2024","unstructured":"Olsen E, Svoboda SA, Montanez-Wiscovich M, Saikaly SK. Multiple eruptive keratoacanthomas secondary to nivolumab immunotherapy. J Immunother. 2024;47(3):98\u2013100. https:\/\/doi.org\/10.1097\/cji.0000000000000498.","journal-title":"J Immunother"},{"issue":"4","key":"1333_CR72","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00403-022-02468-3","volume":"315","author":"M Poole","year":"2023","unstructured":"Poole M, Schwartz RA, Lambert WC, Alhatem A. To treat or not to treat: PD-L1 inhibitor-induced keratoacanthoma and squamous cell carcinoma. Arch Dermatol Res. 2023;315(4):903\u201315. https:\/\/doi.org\/10.1007\/s00403-022-02468-3.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1333_CR73","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"F Su","year":"2012","unstructured":"Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1105358.","journal-title":"N Engl J Med"},{"issue":"6","key":"1333_CR74","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","volume":"24","author":"L Boussemart","year":"2013","unstructured":"Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdt015.","journal-title":"Ann Oncol"},{"issue":"11","key":"1333_CR75","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/jamadermatol.2014.838","volume":"150","author":"FW Chen","year":"2014","unstructured":"Chen FW, Tseng D, Reddy S, Daud AI, Swetter SM. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatol. 2014;150(11):1209\u201312. https:\/\/doi.org\/10.1001\/jamadermatol.2014.838.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1333_CR76","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40264-019-00806-5","volume":"42","author":"KM Blakely","year":"2019","unstructured":"Blakely KM, Drucker AM, Rosen CF. Drug-Induced Photosensitivity-An update: culprit drugs, prevention and management. Drug Saf. 2019;42(7):827\u201347. https:\/\/doi.org\/10.1007\/s40264-019-00806-5.","journal-title":"Drug Saf"},{"issue":"Suppl 6","key":"1333_CR77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/jdv.18200","volume":"36","author":"V Sibaud","year":"2022","unstructured":"Sibaud V. Anticancer treatments and photosensitivity. J Eur Acad Dermatol Venereol. 2022;36(Suppl 6):51\u20138. https:\/\/doi.org\/10.1111\/jdv.18200.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1333_CR78","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/bjd.13300","volume":"171","author":"C Brugi\u00e8re","year":"2014","unstructured":"Brugi\u00e8re C, Stefan A, Morice C, Cornet E, Moreau A, Allouche S, et al. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease. Br J Dermatol. 2014;171(6):1529\u201332. https:\/\/doi.org\/10.1111\/bjd.13300.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1333_CR79","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/ddg.14140","volume":"18","author":"B Eberlein","year":"2020","unstructured":"Eberlein B, Biedermann T, Hein R, Posch C. Vemurafenib-related photosensitivity. J Dtsch Dermatol Ges. 2020;18(10):1079\u201383. https:\/\/doi.org\/10.1111\/ddg.14140.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"1333_CR80","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1007\/s00520-022-06841-w","volume":"30","author":"C Park","year":"2022","unstructured":"Park C, Korman AM, Dulmage BL. An overview of the efficacy of phototherapy in oncodermatology. Support Care Cancer. 2022;30(7):5591\u2013600. https:\/\/doi.org\/10.1007\/s00520-022-06841-w.","journal-title":"Support Care Cancer"},{"issue":"42","key":"1333_CR81","doi-asserted-by":"publisher","first-page":"e31208","DOI":"10.1097\/md.0000000000031208","volume":"101","author":"TH Liu","year":"2022","unstructured":"Liu TH, Wu SY, Tsai SL, Wu CW, Hou CC, Lai CY, et al. Effective and enduring surgical treatment for targeted therapy-related paronychia: A retrospective study. Med (Baltim). 2022;101(42):e31208. https:\/\/doi.org\/10.1097\/md.0000000000031208.","journal-title":"Med (Baltim)"},{"key":"1333_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.01.069","author":"EN Axler","year":"2025","unstructured":"Axler EN, Iorizzo M, McLellan B, Lipner SR. Nail toxicity associated with anticancer agents. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.069.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1333_CR83","first-page":"35","volume":"12","author":"B Sampson","year":"2019","unstructured":"Sampson B, Lewis BKH. Paronychia associated with ledipasvir\/sofosbuvir for hepatitis C treatment. J Clin Aesthet Dermatol. 2019;12(1):35\u20137.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1333_CR84","doi-asserted-by":"publisher","first-page":"212613","DOI":"10.7573\/dic.212613","volume":"8","author":"P Sollena","year":"2019","unstructured":"Sollena P, Mannino M, Tassone F, Calegari MA, D\u2019Argento E, Peris K. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. Drugs Context. 2019;8:212613. https:\/\/doi.org\/10.7573\/dic.212613.","journal-title":"Drugs Context"},{"issue":"3","key":"1333_CR85","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/ijd.14730","volume":"59","author":"CF Yen","year":"2020","unstructured":"Yen CF, Hsu CK, Yang HS, Lee CN, Chi CC, Chung WH, et al. Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. Int J Dermatol. 2020;59(3):326\u201332. https:\/\/doi.org\/10.1111\/ijd.14730.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1333_CR86","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/ijd.IJD_348_18","volume":"65","author":"I Kaur","year":"2020","unstructured":"Kaur I, Gandhi V, Jakhar D. Acute Paronychia and reactive capillary proliferation in a patient on erlotinib. Indian J Dermatol. 2020;65(3):236\u20137. https:\/\/doi.org\/10.4103\/ijd.IJD_348_18.","journal-title":"Indian J Dermatol"},{"issue":"3","key":"1333_CR87","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5021\/ad.2019.31.3.347","volume":"31","author":"SY Lee","year":"2019","unstructured":"Lee SY, Kim JW, Yu DS, Lee YB. Alitretinoin treatment for Gefitinib-Induced Paronychia. Ann Dermatol. 2019;31(3):347\u20138. https:\/\/doi.org\/10.5021\/ad.2019.31.3.347.","journal-title":"Ann Dermatol"},{"issue":"6","key":"1333_CR88","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/dss.0000000000003036","volume":"47","author":"HL Hanania","year":"2021","unstructured":"Hanania HL, Pacha O, Heberton M, Patel AB. Surgical intervention for Paronychia induced by targeted anticancer therapies. Dermatol Surg. 2021;47(6):775\u20139. https:\/\/doi.org\/10.1097\/dss.0000000000003036.","journal-title":"Dermatol Surg"},{"issue":"5","key":"1333_CR89","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/jamadermatol.2022.0725","volume":"158","author":"A Agematsu","year":"2022","unstructured":"Agematsu A, Kamata M, Namiki K, Yabuuchi Y, Nagata M, Tada Y. Usefulness of noninvasive management with the gutter method for epidermal growth factor receptor Inhibitor-Induced paronychia, pyogenic Granuloma-Like lesion, and ingrown nail. JAMA Dermatol. 2022;158(5):583\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0725.","journal-title":"JAMA Dermatol"},{"key":"1333_CR90","doi-asserted-by":"publisher","first-page":"1414136","DOI":"10.3389\/fimmu.2024.1414136","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou J, Wang CP, Li J, Zhang HL, He CX. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review. Front Immunol. 2024;15:1414136. https:\/\/doi.org\/10.3389\/fimmu.2024.1414136.","journal-title":"Front Immunol"},{"issue":"11","key":"1333_CR91","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/j.1346-8138.1999.tb02082.x","volume":"26","author":"JC Roujeau","year":"1999","unstructured":"Roujeau JC. Treatment of severe drug eruptions. J Dermatol. 1999;26(11):718\u201322. https:\/\/doi.org\/10.1111\/j.1346-8138.1999.tb02082.x.","journal-title":"J Dermatol"},{"issue":"7","key":"1333_CR92","doi-asserted-by":"publisher","first-page":"e27747","DOI":"10.1002\/pbc.27747","volume":"66","author":"TP Miller","year":"2019","unstructured":"Miller TP, Fisher BT, Getz KD, Sack L, Razzaghi H, Seif AE, et al. Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer. 2019;66(7):e27747. https:\/\/doi.org\/10.1002\/pbc.27747.","journal-title":"Pediatr Blood Cancer"},{"key":"1333_CR93","doi-asserted-by":"publisher","unstructured":"Pacholczak-Madej R, Kosa\u0142ka-W\u0119giel J, Kuszmiersz P, Mitu\u015b JW, P\u00fcsk\u00fcll\u00fco\u011flu M, Grela-Wojewoda A, et al. Immune checkpoint inhibitor related rheumatological complications: Cooperation between rheumatologists and oncologists. Int J Environ Res Public Health. 2023;20(6). https:\/\/doi.org\/10.3390\/ijerph20064926.","DOI":"10.3390\/ijerph20064926"},{"issue":"4","key":"1333_CR94","doi-asserted-by":"publisher","first-page":"101805","DOI":"10.1016\/j.berh.2022.101805","volume":"36","author":"P Reid","year":"2022","unstructured":"Reid P, Cappelli LC. Treatment of rheumatic adverse events of cancer immunotherapy. Best Pract Res Clin Rheumatol. 2022;36(4):101805. https:\/\/doi.org\/10.1016\/j.berh.2022.101805.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"1333_CR95","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jtct.2024.06.024","volume":"30","author":"R Storgard","year":"2024","unstructured":"Storgard R, Dusza S, Shouval R, Scordo M, Markova A. Dermatologic adverse events associated with chimeric antigen receptor T-Cell therapy: A pharmacovigilance analysis of the FDA reporting system. Transpl Cell Ther. 2024;30(10):1035.e1-.e7 https:\/\/doi.org\/10.1016\/j.jtct.2024.06.024.","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"1333_CR96","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40257-022-00736-6","volume":"24","author":"RG Micheletti","year":"2023","unstructured":"Micheletti RG. Cutaneous small vessel vasculitis: A practical guide to diagnosis and management. Am J Clin Dermatol. 2023;24(1):89\u201395. https:\/\/doi.org\/10.1007\/s40257-022-00736-6.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1333_CR97","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/dad.0000000000000023","volume":"36","author":"B Choy","year":"2014","unstructured":"Choy B, Chou S, Anforth R, Fern\u00e1ndez-Pe\u00f1as P. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36(6):493\u20137. https:\/\/doi.org\/10.1097\/dad.0000000000000023.","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"1333_CR98","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","volume":"148","author":"L Zimmer","year":"2012","unstructured":"Zimmer L, Livingstone E, Hillen U, D\u00f6mkes S, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148(3):357\u201361. https:\/\/doi.org\/10.1001\/archdermatol.2011.2842.","journal-title":"Arch Dermatol"},{"issue":"6","key":"1333_CR99","doi-asserted-by":"publisher","first-page":"e62027","DOI":"10.7759\/cureus.62027","volume":"16","author":"S Muralidharan","year":"2024","unstructured":"Muralidharan S, Mariano AT, Joshi D, Andrews TE, Liu S, Basha A, et al. A rare case of Drug-Induced sweet syndrome after pembrolizumab therapy. Cureus. 2024;16(6):e62027. https:\/\/doi.org\/10.7759\/cureus.62027.","journal-title":"Cureus"},{"issue":"1","key":"1333_CR100","doi-asserted-by":"publisher","first-page":"e14461","DOI":"10.1111\/dth.14461","volume":"34","author":"JJ Yang","year":"2021","unstructured":"Yang JJ, Maloney NJ, Nguyen KA, Worswick S, Smogorzewski J, Bach DQ. Sweet syndrome as an adverse reaction to tyrosine kinase inhibitors: A review. Dermatol Ther. 2021;34(1):e14461. https:\/\/doi.org\/10.1111\/dth.14461.","journal-title":"Dermatol Ther"},{"key":"1333_CR101","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1750-1172-2-34","volume":"2","author":"PR Cohen","year":"2007","unstructured":"Cohen PR. Sweet\u2019s syndrome\u2013a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34. https:\/\/doi.org\/10.1186\/1750-1172-2-34.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1333_CR102","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.critrevonc.2012.09.005","volume":"86","author":"S Paydas","year":"2013","unstructured":"Paydas S. Sweet\u2019s syndrome: a revisit for hematologists and oncologists. Crit Rev Oncol Hematol. 2013;86(1):85\u201395. https:\/\/doi.org\/10.1016\/j.critrevonc.2012.09.005.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"1333_CR103","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/cup.12273","volume":"41","author":"P Pattanaprichakul","year":"2014","unstructured":"Pattanaprichakul P, Tetzlaff MT, Lapolla WJ, Torres-Cabala CA, Duvic M, Prieto VG, et al. Sweet syndrome following Vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol. 2014;41(3):326\u20138. https:\/\/doi.org\/10.1111\/cup.12273.","journal-title":"J Cutan Pathol"},{"issue":"6","key":"1333_CR104","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/cmr.0000000000000017","volume":"23","author":"S Pintova","year":"2013","unstructured":"Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet\u2019s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013;23(6):498\u2013501. https:\/\/doi.org\/10.1097\/cmr.0000000000000017.","journal-title":"Melanoma Res"},{"issue":"10","key":"1333_CR105","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00403-024-03414-1","volume":"316","author":"Z Wu","year":"2024","unstructured":"Wu Z, Sun W, He B, Wang C. Clinical features, treatment, and outcome of granulocyte colony stimulating factor-induced sweet syndrome. Arch Dermatol Res. 2024;316(10):685. https:\/\/doi.org\/10.1007\/s00403-024-03414-1.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1333_CR106","doi-asserted-by":"publisher","first-page":"e13074","DOI":"10.1111\/dth.13074","volume":"32","author":"V Ravi","year":"2019","unstructured":"Ravi V, Maloney NJ, Worswick S. Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review. Dermatol Ther. 2019;32(5):e13074. https:\/\/doi.org\/10.1111\/dth.13074.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1333_CR107","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","volume":"158","author":"K Tang","year":"2022","unstructured":"Tang K, Seo J, Tiu BC, Le TK, Pahalyants V, Raval NS, et al. Association of cutaneous Immune-Related adverse events with increased survival in patients treated with Anti-Programmed cell death 1 and Anti-Programmed cell death ligand 1 therapy. JAMA Dermatol. 2022;158(2):189\u201393. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5476.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1333_CR108","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.abd.2022.10.004","volume":"98","author":"JK Recuero","year":"2023","unstructured":"Recuero JK, Fitz JR, Pereira AA, Bonamigo RR. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects. Bras Dermatol. 2023;98(4):429\u201339. https:\/\/doi.org\/10.1016\/j.abd.2022.10.004.","journal-title":"Bras Dermatol"},{"issue":"3","key":"1333_CR109","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ctrv.2010.08.004","volume":"37","author":"BL Ramaekers","year":"2011","unstructured":"Ramaekers BL, Pijls-Johannesma M, Joore MA, van den Ende P, Langendijk JA, Lambin P, et al. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons. Cancer Treat Rev. 2011;37(3):185\u2013201. https:\/\/doi.org\/10.1016\/j.ctrv.2010.08.004.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"1333_CR110","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMra1608986","volume":"377","author":"DE Citrin","year":"2017","unstructured":"Citrin DE. Recent developments in radiotherapy. N Engl J Med. 2017;377(11):1065\u201375. https:\/\/doi.org\/10.1056\/NEJMra1608986.","journal-title":"N Engl J Med"},{"key":"1333_CR111","doi-asserted-by":"publisher","unstructured":"Boopathi E, Den RB, Thangavel C. Innate immune system in the context of radiation therapy for Cancer. Cancers (Basel). 2023;15(15). https:\/\/doi.org\/10.3390\/cancers15153972.","DOI":"10.3390\/cancers15153972"},{"issue":"3","key":"1333_CR112","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40257-016-0186-4","volume":"17","author":"M Singh","year":"2016","unstructured":"Singh M, Alavi A, Wong R, Akita S, Radiodermatitis. A review of our current Understanding. Am J Clin Dermatol. 2016;17(3):277\u201392. https:\/\/doi.org\/10.1007\/s40257-016-0186-4.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1333_CR113","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jaad.2005.08.054","volume":"54","author":"SR Hymes","year":"2006","unstructured":"Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol. 2006;54(1):28\u201346. https:\/\/doi.org\/10.1016\/j.jaad.2005.08.054.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1333_CR114","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s0167-8140(01)00327-9","volume":"59","author":"A Bostr\u00f6m","year":"2001","unstructured":"Bostr\u00f6m A, Lindman H, Swartling C, Berne B, Bergh J. Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. Radiother Oncol. 2001;59(3):257\u201365. https:\/\/doi.org\/10.1016\/s0167-8140(01)00327-9.","journal-title":"Radiother Oncol"},{"key":"1333_CR115","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/cmar.S188655","volume":"11","author":"J Wei","year":"2019","unstructured":"Wei J, Meng L, Hou X, Qu C, Wang B, Xin Y, et al. Radiation-induced skin reactions: mechanism and treatment. Cancer Manag Res. 2019;11:167\u201377. https:\/\/doi.org\/10.2147\/cmar.S188655.","journal-title":"Cancer Manag Res."},{"issue":"5","key":"1333_CR116","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ijwd.2020.07.015","volume":"6","author":"JY Ramseier","year":"2020","unstructured":"Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. Int J Womens Dermatol. 2020;6(5):349\u201356. https:\/\/doi.org\/10.1016\/j.ijwd.2020.07.015.","journal-title":"Int J Womens Dermatol"},{"issue":"11","key":"1333_CR117","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00432-015-1974-6","volume":"141","author":"JM Straub","year":"2015","unstructured":"Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: mechanisms and implications for therapy. J Cancer Res Clin Oncol. 2015;141(11):1985\u201394. https:\/\/doi.org\/10.1007\/s00432-015-1974-6.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1333_CR118","first-page":"4","volume":"29","author":"JJ Feldmeier","year":"2002","unstructured":"Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. Undersea Hyperb Med. 2002;29(1):4\u201330.","journal-title":"Undersea Hyperb Med"},{"issue":"1","key":"1333_CR119","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/cup.13363","volume":"46","author":"S Ronen","year":"2019","unstructured":"Ronen S, Ivan D, Torres-Cabala CA, Curry JL, Tetzlaff MT, Aung PP, et al. Post-radiation vascular lesions of the breast. J Cutan Pathol. 2019;46(1):52\u20138. https:\/\/doi.org\/10.1111\/cup.13363.","journal-title":"J Cutan Pathol"},{"issue":"4","key":"1333_CR120","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1053\/j.semdp.2023.04.017","volume":"40","author":"CD Rutland","year":"2023","unstructured":"Rutland CD, Bean GR, Charville GW. Contemporary diagnostic approach to atypical vascular lesion and angiosarcoma. Semin Diagn Pathol. 2023;40(4):284\u201394. https:\/\/doi.org\/10.1053\/j.semdp.2023.04.017.","journal-title":"Semin Diagn Pathol"},{"issue":"4","key":"1333_CR121","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/cco.0000000000000958","volume":"35","author":"A Dufresne","year":"2023","unstructured":"Dufresne A, Meeus P, Sunyach MP. Treatment of radiation-associated angiosarcoma. Curr Opin Oncol. 2023;35(4):296\u2013300. https:\/\/doi.org\/10.1097\/cco.0000000000000958.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"1333_CR122","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/jdv.12704","volume":"29","author":"M Spalek","year":"2015","unstructured":"Spalek M, Jonska-Gmyrek J, Ga\u0142ecki J. Radiation-induced morphea - a literature review. J Eur Acad Dermatol Venereol. 2015;29(2):197\u2013202. https:\/\/doi.org\/10.1111\/jdv.12704.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1333_CR123","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40257-020-00519-x","volume":"21","author":"KA Ashack","year":"2020","unstructured":"Ashack KA, Kuritza V, Visconti MJ, Ashack L. Dermatologic sequelae associated with radiation therapy. Am J Clin Dermatol. 2020;21(4):541\u201355. https:\/\/doi.org\/10.1007\/s40257-020-00519-x.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1333_CR124","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/ced.12345","volume":"39","author":"D Lim","year":"2014","unstructured":"Lim D, Johnston S, Novakovic L, Fearfield L. Radiation-induced morphoea treated with UVA-1 phototherapy. Clin Exp Dermatol. 2014;39(5):612\u20135. https:\/\/doi.org\/10.1111\/ced.12345.","journal-title":"Clin Exp Dermatol"},{"key":"1333_CR125","doi-asserted-by":"publisher","first-page":"107399","DOI":"10.1016\/j.pharmthera.2019.107399","volume":"204","author":"A Ejaz","year":"2019","unstructured":"Ejaz A, Greenberger JS, Rubin PJ. Understanding the mechanism of radiation induced fibrosis and therapy options. Pharmacol Ther. 2019;204:107399. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107399.","journal-title":"Pharmacol Ther"},{"key":"1333_CR126","doi-asserted-by":"publisher","first-page":"109560","DOI":"10.1016\/j.biopha.2019.109560","volume":"121","author":"B Wang","year":"2020","unstructured":"Wang B, Wei J, Meng L, Wang H, Qu C, Chen X, et al. Advances in pathogenic mechanisms and management of radiation-induced fibrosis. Biomed Pharmacother. 2020;121:109560. https:\/\/doi.org\/10.1016\/j.biopha.2019.109560.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1333_CR127","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/lsm.23617","volume":"55","author":"B Wilson","year":"2023","unstructured":"Wilson B, Shah R, Menzer C, Aleisa A, Rossi A. Laser therapy as a treatment for chronic radiation fibrosis. Lasers Surg Med. 2023;55(1):82\u20138. https:\/\/doi.org\/10.1002\/lsm.23617.","journal-title":"Lasers Surg Med"},{"issue":"2","key":"1333_CR128","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00221-010-2471-4","volume":"208","author":"JL Stephenson","year":"2011","unstructured":"Stephenson JL, Christou EA, Maluf KS. Discharge rate modulation of trapezius motor units differs for voluntary contractions and instructed muscle rest. Exp Brain Res. 2011;208(2):203\u201315. https:\/\/doi.org\/10.1007\/s00221-010-2471-4.","journal-title":"Exp Brain Res"},{"key":"1333_CR129","doi-asserted-by":"publisher","first-page":"114172","DOI":"10.1016\/j.ejca.2024.114172","volume":"207","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden RJ, Burgers FH, Janssen JC, Putker AE, Veenstra S, Hospers GAP, et al. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma. Eur J Cancer. 2024;207:114172. https:\/\/doi.org\/10.1016\/j.ejca.2024.114172.","journal-title":"Eur J Cancer"},{"issue":"31","key":"1333_CR130","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1200\/jco.24.00191","volume":"42","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden RJ, de Groot JS, Fabriek BO, Hew MN, May AM, Suijkerbuijk KPM. Corticosteroids for Immune-Related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials. J Clin Oncol. 2024;42(31):3713\u201324. https:\/\/doi.org\/10.1200\/jco.24.00191.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1333_CR131","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.Ccr-19-3322","volume":"26","author":"RJ Verheijden","year":"2020","unstructured":"Verheijden RJ, May AM, Blank CU, Aarts MJB, van den Berkmortel F, van den Eertwegh AJM, et al. Association of Anti-TNF with decreased survival in steroid refractory ipilimumab and Anti-PD1-Treated patients in the Dutch melanoma treatment registry. Clin Cancer Res. 2020;26(9):2268\u201374. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3322.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1333_CR132","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","volume":"6","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6(1):37. https:\/\/doi.org\/10.1186\/s40425-018-0346-6.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1333_CR133","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","volume":"6","author":"DH Johnson","year":"2018","unstructured":"Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL Jr., Abdel-Wahab N, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related Enterocolitis. J Immunother Cancer. 2018;6(1):103. https:\/\/doi.org\/10.1186\/s40425-018-0412-0.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1333_CR134","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/cncr.34742","volume":"129","author":"S Lev-Ari","year":"2023","unstructured":"Lev-Ari S, Serzan M, Wu T, Ip A, Pascual L, Sinclaire B, et al. The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study. Cancer. 2023;129(12):1885\u201394. https:\/\/doi.org\/10.1002\/cncr.34742.","journal-title":"Cancer"},{"issue":"1","key":"1333_CR135","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50(1):5\u201314. https:\/\/doi.org\/10.1111\/cea.13491.","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"1333_CR136","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jaip.2022.12.018","volume":"11","author":"S Owji","year":"2023","unstructured":"Owji S, Ungar B, Dubin DP, Poplausky D, Young JN, Ghalili S, et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract. 2023;11(5):1548\u201351. https:\/\/doi.org\/10.1016\/j.jaip.2022.12.018.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1333_CR137","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jdcr.2024.11.033","volume":"57","author":"E Bogdanski","year":"2025","unstructured":"Bogdanski E, Viveiros MD, Chung C, Dulmage B. Immune checkpoint inhibitor induced bullous pemphigoid treated by dupilumab: A case series. JAAD Case Rep. 2025;57:90\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2024.11.033.","journal-title":"JAAD Case Rep."},{"issue":"6","key":"1333_CR138","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaad.2022.08.001","volume":"87","author":"D Bur","year":"2022","unstructured":"Bur D, Patel AB, Nelson K, Huen A, Pacha O, Phillips R, et al. A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes. J Am Acad Dermatol. 2022;87(6):1394\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.001.","journal-title":"J Am Acad Dermatol"},{"key":"1333_CR139","doi-asserted-by":"publisher","first-page":"2050313x2311954","DOI":"10.1177\/2050313x231195462","volume":"11","author":"C Fournier","year":"2023","unstructured":"Fournier C, Hirsch I, Spreafico A, Butler MO, Dhani N, Sauder MB. Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature. SAGE Open Med Case Rep. 2023;11:2050313x231195462. https:\/\/doi.org\/10.1177\/2050313x231195462.","journal-title":"SAGE Open Med Case Rep"},{"key":"1333_CR140","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdcr.2023.05.004","volume":"37","author":"JJ Park","year":"2023","unstructured":"Park JJ, Park E, Damsky WE, Vesely MD. Pembrolizumab-induced lichenoid dermatitis treated with dupilumab. JAAD Case Rep. 2023;37:13\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2023.05.004.","journal-title":"JAAD Case Rep."},{"issue":"1","key":"1333_CR141","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135\u201341. https:\/\/doi.org\/10.1016\/j.jaci.2018.05.029.","journal-title":"J Allergy Clin Immunol"},{"key":"1333_CR142","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00927-x","author":"ATM R\u00f8nnstad","year":"2025","unstructured":"R\u00f8nnstad ATM, Bunick CG, Chovatiya R, Kamata M, Nielsen ML, Isufi D, et al. Real-World evidence of tralokinumab effectiveness and safety: A systematic review and Meta-analysis. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/s40257-025-00927-x.","journal-title":"Am J Clin Dermatol"},{"key":"1333_CR143","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/ccid.S511559","volume":"18","author":"G Lauletta","year":"2025","unstructured":"Lauletta G, Potestio L, Patruno C, De Lucia M, Napolitano M. Effectiveness and safety of dupilumab and tralokinumab for treating atopic dermatitis and pruritic skin disorders in oncological patients: A narrative review. Clin Cosmet Investig Dermatol. 2025;18:311\u20137. https:\/\/doi.org\/10.2147\/ccid.S511559.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"1333_CR144","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/der.0000000000000845","volume":"33","author":"AM Drucker","year":"2022","unstructured":"Drucker AM, Lam M, Flohr C, Thyssen JP, Kabashima K, Bissonnette R, et al. Systemic therapy for atopic dermatitis in older adults and adults with comorbidities: A scoping review and international eczema Council survey. Dermatitis. 2022;33(3):200\u20136. https:\/\/doi.org\/10.1097\/der.0000000000000845.","journal-title":"Dermatitis"},{"issue":"1","key":"1333_CR145","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","volume":"83","author":"ML Espinosa","year":"2020","unstructured":"Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.050.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1333_CR146","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jamadermatol.2023.3849","volume":"159","author":"CM Boesjes","year":"2023","unstructured":"Boesjes CM, van der Gang LF, Bakker DS, Ten Cate TA, Spekhorst LS, de Graaf M, et al. Dupilumab-Associated lymphoid reactions in patients with atopic dermatitis. JAMA Dermatol. 2023;159(11):1240\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3849.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1333_CR147","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1111\/ijd.16538","volume":"62","author":"M Ahmad","year":"2023","unstructured":"Ahmad M, Murphy MJ, Damsky W, Leventhal J. Dupilumab-induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression. Int J Dermatol. 2023;62(8):e424\u20136. https:\/\/doi.org\/10.1111\/ijd.16538.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1333_CR148","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/bjd\/ljad324","volume":"190","author":"CF Guerrero-Juarez","year":"2023","unstructured":"Guerrero-Juarez CF, Goyal PK, Amber KT. Targeting Interleukin (IL)-4\/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy. Br J Dermatol. 2023;190(1):137\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad324.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1333_CR149","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","volume":"39","author":"J Corren","year":"2009","unstructured":"Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of Omalizumab. Clin Exp Allergy. 2009;39(6):788\u201397. https:\/\/doi.org\/10.1111\/j.1365-2222.2009.03214.x.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"1333_CR150","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","volume":"132","author":"A Kaplan","year":"2013","unstructured":"Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2013.05.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1333_CR151","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","volume":"32","author":"DM Barrios","year":"2021","unstructured":"Barrios DM, Phillips GS, Geisler AN, Trelles SR, Markova A, Noor SJ, et al. IgE Blockade with Omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol. 2021;32(6):736\u201345. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.016.","journal-title":"Ann Oncol"},{"issue":"4","key":"1333_CR152","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/bjd.20941","volume":"186","author":"Z Ali","year":"2022","unstructured":"Ali Z, Egeberg A, Thyssen JP, S\u00f8rensen JA, Vestergaard C, Thomsen SF. No association between Omalizumab use and risk of cancer: a nationwide registry-based cohort study. Br J Dermatol. 2022;186(4):746\u20138. https:\/\/doi.org\/10.1111\/bjd.20941.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1333_CR153","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/cea.13457","volume":"49","author":"A Johnston","year":"2019","unstructured":"Johnston A, Smith C, Zheng C, Aaron SD, Kelly SE, Skidmore B, et al. Influence of prolonged treatment with Omalizumab on the development of solid epithelial cancer in patients with atopic asthma and chronic idiopathic urticaria: A systematic review and meta-analysis. Clin Exp Allergy. 2019;49(10):1291\u2013305. https:\/\/doi.org\/10.1111\/cea.13457.","journal-title":"Clin Exp Allergy"},{"key":"1333_CR154","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","volume":"13 Suppl 2","author":"T Cerny","year":"2002","unstructured":"Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 2002;13 Suppl 2:S3-10. https:\/\/doi.org\/10.1097\/00001813-200211002-00002.","journal-title":"Anticancer Drugs."},{"issue":"6","key":"1333_CR155","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","volume":"153","author":"L Sowerby","year":"2017","unstructured":"Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR. Rituximab treatment of Nivolumab-Induced bullous pemphigoid. JAMA Dermatol. 2017;153(6):603\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0091.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1333_CR156","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00520-021-06548-4","volume":"30","author":"JJ Lo","year":"2022","unstructured":"Lo JJ, Heberton MM, Pacha O, Huen AO, Patel AB. Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients. Support Care Cancer. 2022;30(2):989\u201394. https:\/\/doi.org\/10.1007\/s00520-021-06548-4.","journal-title":"Support Care Cancer"},{"issue":"8","key":"1333_CR157","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/ijd.16714","volume":"62","author":"R Mital","year":"2023","unstructured":"Mital R, Otto TS, Savu A, Baumrin E, Cardones AR, Carlesimo M, et al. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management. Int J Dermatol. 2023;62(8):1020\u20135. https:\/\/doi.org\/10.1111\/ijd.16714.","journal-title":"Int J Dermatol"},{"issue":"11","key":"1333_CR158","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/ijd.13970","volume":"57","author":"AV Ridpath","year":"2018","unstructured":"Ridpath AV, Rzepka PV, Shearer SM, Scrape SR, Olencki TE, Kaffenberger BH. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid. Int J Dermatol. 2018;57(11):1372\u20134. https:\/\/doi.org\/10.1111\/ijd.13970.","journal-title":"Int J Dermatol"},{"issue":"10","key":"1333_CR159","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jdcr.2019.07.015","volume":"5","author":"S Singer","year":"2019","unstructured":"Singer S, Nelson CA, Lian CG, Dewan AK, LeBoeuf NR. Nonbullous pemphigoid secondary to PD-1 Inhibition. JAAD Case Rep. 2019;5(10):898\u2013903. https:\/\/doi.org\/10.1016\/j.jdcr.2019.07.015.","journal-title":"JAAD Case Rep"},{"issue":"11","key":"1333_CR160","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1200\/jop.19.00751","volume":"16","author":"P Sharma","year":"2020","unstructured":"Sharma P, Barnes M, Nabeel S, LiPera W. Pembrolizumab-Induced bullous pemphigoid treated with rituximab. JCO Oncol Pract. 2020;16(11):764\u20136. https:\/\/doi.org\/10.1200\/jop.19.00751.","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"1333_CR161","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jdcr.2020.01.008","volume":"6","author":"CA Virgen","year":"2020","unstructured":"Virgen CA, Nguyen TA, Di Raimondo C, Amini A, Margolin KA, Parekh V, et al. Bullous pemphigoid associated with Cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2020;6(3):195\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2020.01.008.","journal-title":"JAAD Case Rep"},{"issue":"9","key":"1333_CR162","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1111\/jdv.17321","volume":"35","author":"E Povilaityte","year":"2021","unstructured":"Povilaityte E, Gellrich FF, Beissert S, Abraham S, Meier F, G\u00fcnther C. Treatment-resistant bullous pemphigoid developing during therapy with immune checkpoint inhibitors. J Eur Acad Dermatol Venereol. 2021;35(9):e591\u20133. https:\/\/doi.org\/10.1111\/jdv.17321.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1333_CR163","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE van Daalen","year":"2017","unstructured":"van Daalen EE, Rizzo R, Kronbichler A, Wolterbeek R, Bruijn JA, Jayne DR, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(6):1064\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209925.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1333_CR164","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","volume":"177","author":"H Wadstr\u00f6m","year":"2017","unstructured":"Wadstr\u00f6m H, Frisell T, Askling J. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from Sweden. JAMA Intern Med. 2017;177(11):1605\u201312. https:\/\/doi.org\/10.1001\/jamainternmed.2017.4332.","journal-title":"JAMA Intern Med"},{"issue":"7","key":"1333_CR165","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1200\/jco.2010.28.9777","volume":"29","author":"C Tarella","year":"2011","unstructured":"Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011;29(7):814\u201324. https:\/\/doi.org\/10.1200\/jco.2010.28.9777.","journal-title":"J Clin Oncol"},{"issue":"10275","key":"1333_CR166","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/s0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerb\u00e4ck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(21)00184-7.","journal-title":"Lancet"},{"issue":"20","key":"1333_CR167","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMc1703047","volume":"376","author":"K Esfahani","year":"2017","unstructured":"Esfahani K, Miller WH. Jr. Reversal of autoimmune toxicity and loss of tumor response by Interleukin-17 Blockade. N Engl J Med. 2017;376(20):1989\u201391. https:\/\/doi.org\/10.1056\/NEJMc1703047.","journal-title":"N Engl J Med"},{"issue":"10","key":"1333_CR168","doi-asserted-by":"publisher","first-page":"e5824","DOI":"10.7759\/cureus.5824","volume":"11","author":"EP Monsour","year":"2019","unstructured":"Monsour EP, Pothen J, Balaraman R. A novel approach to the treatment of Pembrolizumab-induced psoriasis exacerbation: A case report. Cureus. 2019;11(10):e5824. https:\/\/doi.org\/10.7759\/cureus.5824.","journal-title":"Cureus"},{"issue":"10","key":"1333_CR169","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/1346-8138.16832","volume":"50","author":"Y Kochi","year":"2023","unstructured":"Kochi Y, Miyachi H, Tagashira R, Koga H, Ishii N, Sugiura K, et al. Simultaneous development of generalized pustular psoriasis and pemphigoid with multiple autoantibodies in a complete responder of pembrolizumab for lung cancer. J Dermatol. 2023;50(10):1343\u20136. https:\/\/doi.org\/10.1111\/1346-8138.16832.","journal-title":"J Dermatol"},{"issue":"8","key":"1333_CR170","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00262-021-02851-5","volume":"70","author":"S Hoa","year":"2021","unstructured":"Hoa S, Laaouad L, Roberts J, Ennis D, Ye C, Al Jumaily K, et al. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a National case series from the Canadian research group of rheumatology in Immuno-Oncology. Cancer Immunol Immunother. 2021;70(8):2197\u2013207. https:\/\/doi.org\/10.1007\/s00262-021-02851-5.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"1333_CR171","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1684\/ejd.2021.4087","volume":"31","author":"A Vinaixa Aranzazu","year":"2021","unstructured":"Vinaixa Aranzazu A, Morillas-Lahuerta V, Blanco De Tord M, Carrascosa Carrillo JM. Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Eur J Dermatol. 2021;31(4):564\u20135. https:\/\/doi.org\/10.1684\/ejd.2021.4087.","journal-title":"Eur J Dermatol"},{"issue":"8","key":"1333_CR172","doi-asserted-by":"publisher","first-page":"e28010","DOI":"10.7759\/cureus.28010","volume":"14","author":"Y Kost","year":"2022","unstructured":"Kost Y, Mattis D, Muskat A, Amin B, McLellan B. Immune checkpoint Inhibitor-Induced psoriasiform, spongiotic, and lichenoid dermatitis: A novel clinicopathological pattern. Cureus. 2022;14(8):e28010. https:\/\/doi.org\/10.7759\/cureus.28010.","journal-title":"Cureus"},{"key":"1333_CR173","doi-asserted-by":"publisher","unstructured":"Ju M, Zhang J, Deng Z, Wei M, Ma L, Chen T, et al. Prophylactic IL-23 Blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. J Immunother Cancer. 2024;12(7). https:\/\/doi.org\/10.1136\/jitc-2024-009345.","DOI":"10.1136\/jitc-2024-009345"},{"issue":"5","key":"1333_CR174","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/cup.14185","volume":"49","author":"RNH Seervai","year":"2022","unstructured":"Seervai RNH, Heberton M, Cho WC, Gill P, Murphy MB, Aung PP, et al. Severe de Novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma. J Cutan Pathol. 2022;49(5):472\u201381. https:\/\/doi.org\/10.1111\/cup.14185.","journal-title":"J Cutan Pathol"},{"key":"1333_CR175","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jdcr.2021.03.029","volume":"11","author":"GD Glinos","year":"2021","unstructured":"Glinos GD, Fisher WS, Morr CS, Seminario-Vidal L. Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma. JAAD Case Rep. 2021;11:74\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2021.03.029.","journal-title":"JAAD Case Rep."},{"issue":"2","key":"1333_CR176","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/cmr.0000000000000875","volume":"33","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Valenti M, Costanzo A, Narcisi A. Pembrolizumab-induced plaque psoriasis successfully treated with Risankizumab in a patient with stage IV cutaneous melanoma. Melanoma Res. 2023;33(2):152\u20134. https:\/\/doi.org\/10.1097\/cmr.0000000000000875.","journal-title":"Melanoma Res"},{"key":"1333_CR177","doi-asserted-by":"publisher","unstructured":"Gu SL, Maier T, Moy AP, Dusza S, Faleck DM, Shah NJ, et al. IL12\/23 Blockade with ustekinumab as a treatment for Immune-Related cutaneous adverse events. Pharmaceuticals (Basel). 2023;16(11). https:\/\/doi.org\/10.3390\/ph16111548.","DOI":"10.3390\/ph16111548"},{"key":"1333_CR178","doi-asserted-by":"publisher","first-page":"1294416","DOI":"10.3389\/fimmu.2023.1294416","volume":"14","author":"S Wu","year":"2023","unstructured":"Wu S, Xu Y, Yang L, Guo L, Jiang X. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Front Immunol. 2023;14:1294416. https:\/\/doi.org\/10.3389\/fimmu.2023.1294416.","journal-title":"Front Immunol"},{"issue":"4","key":"1333_CR179","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"key":"1333_CR180","first-page":"16","volume":"57","author":"BA Beutler","year":"1999","unstructured":"Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl. 1999;57:16\u201321.","journal-title":"J Rheumatol Suppl"},{"issue":"5","key":"1333_CR181","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/cji.0000000000000268","volume":"42","author":"C Lesage","year":"2019","unstructured":"Lesage C, Longvert C, Prey S, Maanaoui S, Dr\u00e9no B, Machet L, et al. Incidence and clinical impact of Anti-TNF\u03b1 treatment of severe immune checkpoint Inhibitor-induced colitis in advanced melanoma: the Mecolit survey. J Immunother. 2019;42(5):175\u20139. https:\/\/doi.org\/10.1097\/cji.0000000000000268.","journal-title":"J Immunother"},{"issue":"1","key":"1333_CR182","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","volume":"7","author":"YR Badran","year":"2019","unstructured":"Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 Blockade in patients with Gastrointestinal immune-related adverse events. J Immunother Cancer. 2019;7(1):226. https:\/\/doi.org\/10.1186\/s40425-019-0711-0.","journal-title":"J Immunother Cancer"},{"key":"1333_CR183","doi-asserted-by":"publisher","first-page":"1421684","DOI":"10.3389\/fimmu.2024.1421684","volume":"15","author":"CX He","year":"2024","unstructured":"He CX, Guo L, Qu T, Jin HZ. Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study. Front Immunol. 2024;15:1421684. https:\/\/doi.org\/10.3389\/fimmu.2024.1421684.","journal-title":"Front Immunol"},{"issue":"6","key":"1333_CR184","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jaad.2022.01.039","volume":"86","author":"S Ao","year":"2022","unstructured":"Ao S, Gao X, Zhan J, Ai L, Li M, Su H, et al. Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis in a cohort of patients. J Am Acad Dermatol. 2022;86(6):1236\u201345. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.039.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1333_CR185","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/jci93349","volume":"128","author":"CW Wang","year":"2018","unstructured":"Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, et al. Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985\u201396. https:\/\/doi.org\/10.1172\/jci93349.","journal-title":"J Clin Invest"},{"issue":"2","key":"1333_CR186","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ajg.2016.537","volume":"112","author":"FA Farraye","year":"2017","unstructured":"Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112(2):241\u201358. https:\/\/doi.org\/10.1038\/ajg.2016.537.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1333_CR187","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.12779","volume":"170","author":"B Nardone","year":"2014","unstructured":"Nardone B, Hammel JA, Raisch DW, Weaver LL, Schneider D, West DP. Melanoma associated with tumour necrosis factor-\u03b1 inhibitors: a research on adverse drug events and reports (RADAR) project. Br J Dermatol. 2014;170(5):1170\u20132. https:\/\/doi.org\/10.1111\/bjd.12779.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1333_CR188","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","volume":"86","author":"MJ Murphy","year":"2022","unstructured":"Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. J Am Acad Dermatol. 2022;86(5):1080\u201391. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.010.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1333_CR189","doi-asserted-by":"publisher","first-page":"e14225","DOI":"10.1111\/dth.14225","volume":"33","author":"N Lian","year":"2020","unstructured":"Lian N, Zhang L, Chen M. Tumor necrosis factors-\u03b1 inhibition-induced Paradoxical psoriasis: A case series and literature review. Dermatol Ther. 2020;33(6):e14225. https:\/\/doi.org\/10.1111\/dth.14225.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1333_CR190","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Med (Baltim). 2007;86(4):242\u201351. https:\/\/doi.org\/10.1097\/MD.0b013e3181441a68.","journal-title":"Med (Baltim)"},{"issue":"1","key":"1333_CR191","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.1038\/s41598-025-90566-3","volume":"15","author":"M He","year":"2025","unstructured":"He M, Yang J, Yan S, Shu Q, Liu PC. Conducting a real-world study of tumor necrosis factor-alpha inhibitors-induced systemic lupus erythematosus based on the FAERS database. Sci Rep. 2025;15(1):6838. https:\/\/doi.org\/10.1038\/s41598-025-90566-3.","journal-title":"Sci Rep"},{"issue":"4","key":"1333_CR192","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-024-00866-z","volume":"25","author":"J Pach","year":"2024","unstructured":"Pach J, Valido K, Belzer A, Leventhal JS. The use of biologic agents for the treatment of cutaneous immune-Related adverse events from immune checkpoint inhibitors: A review of reported cases. Am J Clin Dermatol. 2024;25(4):595\u2013607. https:\/\/doi.org\/10.1007\/s40257-024-00866-z.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1333_CR193","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.36849\/jdd.8617","volume":"23","author":"N Menta","year":"2024","unstructured":"Menta N, Vidal SI, Friedman A. Topical aprepitant (HT-001): A novel therapy for epidermal growth factor receptor Inhibitor-Associated papulopustular eruptions. J Drugs Dermatol. 2024;23(9):e173\u20134. https:\/\/doi.org\/10.36849\/jdd.8617.","journal-title":"J Drugs Dermatol"},{"issue":"752","key":"1333_CR194","doi-asserted-by":"publisher","first-page":"eabq7074","DOI":"10.1126\/scitranslmed.abq7074","volume":"16","author":"Q You","year":"2024","unstructured":"You Q, Chen L, Li S, Liu M, Tian M, Cheng Y, et al. Topical JAK Inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans. Sci Transl Med. 2024;16(752):eabq7074. https:\/\/doi.org\/10.1126\/scitranslmed.abq7074.","journal-title":"Sci Transl Med"},{"issue":"699","key":"1333_CR195","doi-asserted-by":"publisher","first-page":"eabo0684","DOI":"10.1126\/scitranslmed.abo0684","volume":"15","author":"N Friedman","year":"2023","unstructured":"Friedman N, Weinstein-Fudim L, Mostinski Y, Elia J, Cohen S, Steinberg E, et al. Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions. Sci Transl Med. 2023;15(699):eabo0684. https:\/\/doi.org\/10.1126\/scitranslmed.abo0684.","journal-title":"Sci Transl Med"},{"issue":"9","key":"1333_CR196","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/2159-8290.Cd-20-1847","volume":"11","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, et al. Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy. Cancer Discov. 2021;11(9):2158\u201367. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1847.","journal-title":"Cancer Discov"},{"key":"1333_CR197","doi-asserted-by":"publisher","first-page":"102278","DOI":"10.1016\/j.ejon.2023.102278","volume":"63","author":"J Robijns","year":"2023","unstructured":"Robijns J, Lodewijckx J, Claes M, Tuts L, Lenaerts M, Wessels T, et al. Evaluation of a novel skin care product for the management of chemotherapy-related dermatologic toxicities: A quasi-experimental study. Eur J Oncol Nurs. 2023;63:102278. https:\/\/doi.org\/10.1016\/j.ejon.2023.102278.","journal-title":"Eur J Oncol Nurs"},{"key":"1333_CR198","doi-asserted-by":"publisher","first-page":"100699","DOI":"10.1016\/j.ctro.2023.100699","volume":"44","author":"CS Dejonckheere","year":"2024","unstructured":"Dejonckheere CS, Layer JP, Nour Y, Layer K, Glasmacher A, Wiegreffe S, et al. Non-invasive physical plasma for preventing radiation dermatitis in breast cancer: results from an intrapatient-randomised double-blind placebo-controlled trial. Clin Transl Radiat Oncol. 2024;44:100699. https:\/\/doi.org\/10.1016\/j.ctro.2023.100699.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"1333_CR199","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaoncol.2023.6533","volume":"10","author":"C H\u00fclp\u00fcsch","year":"2024","unstructured":"H\u00fclp\u00fcsch C, Neumann AU, Reiger M, Fischer JC, de Tomassi A, Hammel G, et al. Association of skin Microbiome dynamics with radiodermatitis in patients with breast Cancer. JAMA Oncol. 2024;10(4):516\u201321. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6533.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1333_CR200","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/jdv.18835","volume":"37","author":"M Gon\u00e7alo","year":"2023","unstructured":"Gon\u00e7alo M. Zinc supplements May prevent and treat cutaneous toxicities induced by epidermal growth factor receptor inhibitors. J Eur Acad Dermatol Venereol. 2023;37(2):220\u20131. https:\/\/doi.org\/10.1111\/jdv.18835.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1333_CR201","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.jaad.2024.04.070","volume":"91","author":"Y El-Sayes","year":"2024","unstructured":"El-Sayes Y, Joly-Chevrier M, BinJadeed H, Litvinov IV, Netchiporouk E. Zinc supplementation for epidermal growth factor receptor inhibitors induced skin toxicity. J Am Acad Dermatol. 2024;91(3):e69\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.070.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1333_CR202","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/1346-8138.16049","volume":"48","author":"M Tohyama","year":"2021","unstructured":"Tohyama M, Sakaguchi C, Nishina T, Hyodo I. Possible involvement of zinc deficiency in epidermal growth factor receptor inhibitor-induced xerotic dermatitis. J Dermatol. 2021;48(10):1579\u201383. https:\/\/doi.org\/10.1111\/1346-8138.16049.","journal-title":"J Dermatol"},{"issue":"2","key":"1333_CR203","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jaad.2023.06.055","volume":"90","author":"WK Huang","year":"2024","unstructured":"Huang WK, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, et al. Zinc supplementation decreased incidence of grade\u2009\u2265\u20092 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. J Am Acad Dermatol. 2024;90(2):368\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2023.06.055.","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01333-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T07:54:19Z","timestamp":1756886059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01333-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":203,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1333"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01333-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"23 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}